Mark S. Gold

Last updated
Mark S. Gold
Mark S. Gold.jpg
Born1949 (age 74–75)
Education
Scientific career
Institutions

Mark S. Gold (born 1949) is an American physician, professor, author, and researcher on the effects of opioids, cocaine, tobacco, and other drugs as well as food on the brain and behavior. He is married to Janice Finn Gold. [1]

Contents

Gold is a former professor in the Department of Neuroscience, distinguished professor, and chairman of the Department of Psychiatry at the University of Florida College of Medicine, where he founded the Division of Addiction Medicine. [2] [3] His translational research has led to an understanding of the role of the nucleus locus coeruleus in addiction, the discovery of clonidine’s efficacy in opiate withdrawal, and the dopamine depletion hypothesis in understanding cocaine addiction. [4] [5]

Early life and career

Raised in Teaneck, New Jersey, Gold was a 1967 graduate of Teaneck High School, [6] where he was a Varsity Baseball player. Gold matriculated to Washington University in St. Louis where he was an Honors graduate and Phi Beta Kappa. [7] In 1987, Gold was awarded a Distinguished Alumni Award from WUSTL where he majored in Psychology. [8]

He moved to the University of Florida in Gainesville where he worked from December 1970 in the new Department of Neuroscience with Fred King, William Luttge, and Steve Zornetzer looking at overlaps in both the brain's sleep and memory systems. [9] [10]

Gold earned his bachelor’s degree from Washington University in St. Louis and graduated from the University of Florida College of Medicine with his medical degree. [11] [12] He then completed a psychiatry residency and fellowship at Yale School of Medicine. [13]

Gold began his career in research at University of Florida in 1970. He has authored over 1,000 published scientific articles, chapters, and abstracts. [14]

He married Janice Finn in 1971, a Florida native who was born in Coral Gables [15] . 

Gold was a distinguished professor of psychiatry, neuroscience, community health, and family medicine at UF. He became interim chairman and then chair of the UF Department of Psychiatry in 2008. During his tenure, he founded the Division of Addiction Medicine and its treatment program, the Florida Recovery Center. [16] He also started laboratory studies in the UF McKnight Brain Institute on topics including second-hand tobacco smoke, sugar and drug self-administration, and fentanyl and opioid drug-induced anhedonia and reversal. [17] From 2011-2014, Gold was the 17th University of Florida Distinguished Alumni Professor, where he had university-wide responsibilities and was honored by UF Dean Michael Good at the halftime at the UF Gators on Homecoming in 2011 on the 50-Yard Line of UF's Football. [18] [19] [20] [21]

After retiring as a full-time academic in 2014, Gold has continued teaching, research and writing as a University of Florida Emeritus Eminent Scholar, clinical professor at the University of Southern California, Tulane University, and the Washington University School of Medicine Departments of Psychiatry. [22] Dr. Gold is an active member of the National Council at the Washington University School of Medicine’s Public Health Institute. [23]

Research and writing career

Gold’s work has focused on developing scientific laboratory models for understanding drug, food, and other addictions that have led to new treatments. Gold was a lead researcher in the discovery of clonidine’s efficacy in opiate withdrawal and a rationale for opiate withdrawal symptomatology. [4] [24] Clonidine was the first non-opioid medication to reverse acute opioid withdrawal symptoms. [25] He co-authored the dopamine depletion hypothesis (Patent #4/312,878) for cocaine addiction and anhedonia. [5] His work helped lead to a new understanding of how cocaine is addicting and the physiology of cocaine craving and “crashing.” [26]

With colleagues, Gold helped to define the importance of the route of cocaine administration in medicinal uses, safety and abuse potential. [27] Gold and his Yale colleague Dr. Robert Byck studied cocaine levels and responses. [28] He also described the phenomenon of smoking cocaine, mixing cocaine and opioids, and crack use in the United States. [29] Gold started the first national drug helpline with Arnold Washton in 1983, [30] and with NIDA's Director Dr. Bob Shuster, expanded access and breadth of drug hotline to cocaine and heroin in 1987. [31]

Gold is co-editor of the 2012 textbook, Food and Addiction, published by Oxford Press, and has worked to evaluate the hypothesis that hedonistic overeating is a pathological attachment to food like any other addiction. [32] [33] [34] Gold and Kelly Brownell co-chaired the Yale Conference on Food Addiction in 2007, one of the first conferences to discuss food, addiction, and hedonic overeating. [35]

Gold's group had the first report in the medical literature on crack, addiction to second-hand tobacco, and cannabis smoke. [36] [37] Gold has also researched methamphetamine and, with NIDA’s Jean Lud Cadet M.D., described the drug’s long-lasting effects in a series of studies from rodents to human post-mortem; [38] [39] [40] [41] physician and health professionals who have become addicts and their outcomes after treatment; [42] [43] [44] and internet and other behavioral addictions. [45] Additional research interests include the role of exercise in neurodegeneration and recovery, treatment-resistant opioid use disorders, and reward deficiency syndrome. [46] [47] [48] [49] Most recently, Gold and collaborators have identified increasing adulteration in illicit drug supply chain and risks for the user [50] and called for education and prevention in addition to current harm reduction and MAT initiatives in response to the overdose crisis. [51]

He was the editor of the World Federation of Neurology's Journal of Neurological Sciences Special Issue on Addiction Medicine 2020 [52] and also in 2022 as the Editor of the Journals special issue of Psychedelic & Interventional Psychiatry. [53]

Honors and recognitions

Gold was chief scientist of the "Afghanistan National Urban Drug Use Survey" for the US State Department and the Bureau of International Narcotics and Law Enforcement Affairs. The survey identified second- and third-hand opium exposure among children in Kabul and other urban Afghan areas. [54]

Gold worked with Herbert D. Kleber, Deputy Director for Demand Reduction at the White House Office of National Drug Control Policy, to develop prevention, education and treatment programs for the use of medications in addiction treatment. [55] Gold has also worked with DARE, [56] Media Partnership for a Drug Free America, the Center on Addiction and Substance Abuse. [57] Gold was a member of the Board of the Betty Ford Center Foundation in the area of drug use and youth and the DEA Museum, where he was a founding director. [58]

Gold has received Phi Beta Kappa and Alpha Omega Alpha; [59] Addiction Policy Forum Pillar of Excellence Award for research; [60] the John P. McGovern Award for his contributions to public policy, treatment, research and addiction prevention; [61] National Association Addiction Treatment and Policy Lifetime Achievement Award; and the Chinese National Academy of Sciences, International Scientist Award. [62] At the University of Florida, Gold was named a Donald Dizney Eminent Scholar and University Distinguished Professor, with the annual White Coat Ceremony also named in his honor. [63] [64] He was given Inventor Awards from UF’s Office of Technology Transfer, the UF COM Wall of Fame, Exemplary Teaching and Minority Mentoring Awards from the UF College of Medicine, and Inventor Awards from UF’s Office of Technology Transfer. [65] [66] While a full-time U.F. Professor, Gold was awarded numerous patents including the development of systems to improve patient medication compliance and outcomes, [67] new approaches and medications for overeating, [68] and a detector to identify second hand tobacco smoke in the environment.

Gold was a founding director at Viewray, an MR-guided radiotherapy company specializing in oncology, and AxoGen, a company specializing in technologies for peripheral nerve recovery and repair. [69] He continues to present epidemiological research on the opioid and emerging cocaine epidemics and behavioral addictions. [70] [71] Gold has written and lectured on responses to reduce overdose deaths, medication-assisted therapies, and opioid use disorders. [72] [73] He regularly lectures at medical schools; Grand Rounds; [74] [75] and national scientific meetings on opioids, cocaine, and the bench-to-bedside science in eating disorders, obesity, and addictions. [76] [77] [78] Recently, he was editor of the World Federation of Neurology's Journal of Neurological Sciences Special Issue on Addiction Medicine 2020. [79]

Related Research Articles

<span class="mw-page-title-main">Naloxone</span> Opioid receptor antagonist

Naloxone is an opioid antagonist: a medication used to reverse or reduce the effects of opioids. For example, it is used to restore breathing after an opioid overdose. Effects begin within two minutes when given intravenously, five minutes when injected into a muscle, and ten minutes as a nasal spray. Naloxone blocks the effects of opioids for 30 to 90 minutes.

<span class="mw-page-title-main">Clonidine</span> Pharmaceutical drug

Clonidine, sold under the brand name Catapres among others, is an α2A-adrenergic agonist medication used to treat high blood pressure, ADHD, drug withdrawal, menopausal flushing, diarrhea, spasticity, and certain pain conditions. The drug is often prescribed off-label for tics. It is used orally, by injection, or as a transdermal skin patch. Onset of action is typically within an hour with the effects on blood pressure lasting for up to eight hours.

Self-medication, sometime called do-it-yourself (DIY) medicine, is a human behavior in which an individual uses a substance or any exogenous influence to self-administer treatment for physical or psychological conditions, for example headaches or fatigue.

<span class="mw-page-title-main">Opioid use disorder</span> Medical condition

Opioid use disorder (OUD) is a substance use disorder characterized by cravings for opioids, continued use despite physical and/or psychological deterioration, increased tolerance with use, and withdrawal symptoms after discontinuing opioids. Opioid withdrawal symptoms include nausea, muscle aches, diarrhea, trouble sleeping, agitation, and a low mood. Addiction and dependence are important components of opioid use disorder.

<span class="mw-page-title-main">Buprenorphine</span> Opioid used to treat pain & opioid use disorder

Buprenorphine, sold under the brand name Subutex among others, is an opioid used to treat opioid use disorder, acute pain, and chronic pain. It can be used under the tongue (sublingual), in the cheek (buccal), by injection, as a skin patch (transdermal), or as an implant. For opioid use disorder, the patient must have moderate opioid withdrawal symptoms before buprenorphine can be administered under direct observation of a health-care provider.

<span class="mw-page-title-main">Baclofen</span> Medication for muscle movement disorders

Baclofen, sold under the brand name Lioresal among others, is a medication used to treat muscle spasticity such as from a spinal cord injury or multiple sclerosis. It may also be used for hiccups and muscle spasms near the end of life, and off-label to treat alcohol use disorder or opioid withdrawal symptoms. It is taken orally or by intrathecal pump. It is also sometimes used transdermally in combination with gabapentin and clonidine prepared at a compounding pharmacy.

<span class="mw-page-title-main">Naltrexone</span> Medication

Naltrexone, sold under the brand name Revia among others, is a medication primarily used to manage alcohol use or opioid use disorder by reducing cravings and feelings of euphoria associated with substance use disorder. It has also been found effective in the treatment of other addictions and may be used for them off-label. An opioid-dependent person should not receive naltrexone before detoxification. It is taken by mouth or by injection into a muscle. Effects begin within 30 minutes, though a decreased desire for opioids may take a few weeks to occur.

Substance dependence, also known as drug dependence, is a biopsychological situation whereby an individual's functionality is dependent on the necessitated re-consumption of a psychoactive substance because of an adaptive state that has developed within the individual from psychoactive substance consumption that results in the experience of withdrawal and that necessitates the re-consumption of the drug. A drug addiction, a distinct concept from substance dependence, is defined as compulsive, out-of-control drug use, despite negative consequences. An addictive drug is a drug which is both rewarding and reinforcing. ΔFosB, a gene transcription factor, is now known to be a critical component and common factor in the development of virtually all forms of behavioral and drug addictions, but not dependence.

<span class="mw-page-title-main">Nalmefene</span> Opioid antagonist

Nalmefene is a medication that is used in the treatment of opioid overdose and alcohol dependence. Nalmefene belongs to the class of opioid antagonists and can be taken by mouth, administered by injection, or delivered through nasal administration.

Drug detoxification is variously construed or interpreted as a type of "medical" intervention or technique in regards to a physical dependence mediated by a drug; as well as the process and experience of a withdrawal syndrome or any of the treatments for acute drug overdose (toxidrome). The first definition however, in relation to substance dependence and its treatment is arguably a misnomer and even directly contradictory since withdrawal is neither contingent upon nor alleviated through biological excretion or clearance of the drug. In fact, excretion of a given drug from the body is one of the very processes that leads to withdrawal since the syndrome arises largely due to the cessation itself and the drug being absent from the body; especially the blood plasma, not from ‘leftover toxins’ or traces of the drug still being in the system.

<span class="mw-page-title-main">Opioid overdose</span> Toxicity due to excessive consumption of opioids

An opioid overdose is toxicity due to excessive consumption of opioids, such as morphine, codeine, heroin, fentanyl, tramadol, and methadone. This preventable pathology can be fatal if it leads to respiratory depression, a lethal condition that can cause hypoxia from slow and shallow breathing. Other symptoms include small pupils and unconsciousness; however, its onset can depend on the method of ingestion, the dosage and individual risk factors. Although there were over 110,000 deaths in 2017 due to opioids, individuals who survived also faced adverse complications, including permanent brain damage.

Herbert David Kleber was an American psychiatrist and substance abuse researcher. His career, centered on the evidence-based treatment of addiction, focused on scientific approaches in place of punishment and moralisms. His career focused on pathology of addiction to help patients reduce the severe discomforts of withdrawal, avoid relapse and stay in recovery.

<span class="mw-page-title-main">Substance use disorder</span> Continual use of drugs (including alcohol) despite detrimental consequences

Substance use disorder (SUD) is the persistent use of drugs despite the substantial harm and adverse consequences to one's own self and others, as a result of their use. In perspective, the effects of the wrong use of substances that are capable of causing harm to the user or others, have been extensively described in different studies using a variety of terms such as substance use problems, problematic drugs or alcohol use, and substance use disorder.The National Institute of Mental Health (NIMH) states that "Substance use disorder (SUD) is a treatable mental disorder that affects a person's brain and behavior, leading to their inability to control their use of substances like legal or illegal drugs, alcohol, or medications. Symptoms can be moderate to severe, with addiction being the most severe form of SUD".Substance use disorders (SUD) are considered to be a serious mental illness that fluctuates with the age that symptoms first start appearing in an individual, the time during which it exists and the type of substance that is used. It is not uncommon for those who have SUD to also have other mental health disorders. Substance use disorders are characterized by an array of mental/emotional, physical, and behavioral problems such as chronic guilt; an inability to reduce or stop consuming the substance(s) despite repeated attempts; operating vehicles while intoxicated; and physiological withdrawal symptoms. Drug classes that are commonly involved in SUD include: alcohol (alcoholism); cannabis; opioids; stimulants such as nicotine (including tobacco), cocaine and amphetamines; benzodiazepines; barbiturates; and other substances.

<span class="mw-page-title-main">Amphetamine dependence</span> Medical condition

Amphetamine dependence refers to a state of psychological dependence on a drug in the amphetamine class. Stimulants such as amphetamines and cocaine do not cause somatic symptoms upon cessation of use but rather neurological-based mental symptoms.

<span class="mw-page-title-main">Addiction</span> Disorder resulting in compulsive behaviours

Addiction is a neuropsychological disorder characterized by a persistent and intense urge to use a drug or engage in a behavior that produces natural reward, despite substantial harm and other negative consequences. Repetitive drug use often alters brain function in ways that perpetuate craving, and weakens self-control. This phenomenon – drugs reshaping brain function – has led to an understanding of addiction as a brain disorder with a complex variety of psychosocial as well as neurobiological factors that are implicated in addiction's development.

<span class="mw-page-title-main">Elinore McCance-Katz</span> American physician, academic, and government official

Elinore F. McCance-Katz is an American physician, academic, and government official who served as Assistant Secretary of Health and Human Services for Mental Health and Substance Use from 2017 to 2021. Prior to assuming her current role, she was the chief medical officer for the Rhode Island Department of Behavioral Healthcare, Developmental Disabilities, and Hospitals and a professor at the Alpert Medical School at Brown University. Her nomination was supported by the American Psychiatric Association, which released a statement saying "Dr. McCance-Katz has a wealth of experience in academic and public sector settings in addressing mental health and substance use disorders."

Nancy M. Petry was a psychologist known for her research on behavioral treatments for addictive disorders, behavioral pharmacology, impulsivity and compulsive gambling. She was Professor of Medicine at the University of Connecticut Health Center. Petry served as a member of the American Psychiatric Association Workgroup on Substance Use Disorders for the DSM-5 and chaired the Subcommittee on Non-Substance Behavioral Addictions. The latter category includes Internet addiction disorder and problem gambling. She also served as a member of the Board of Advisors of Children and Screens: Institute of Digital Media and Child Development.

Robert D. Kerns is an American clinical psychologist, academic and author. He is Professor Emeritus of Psychiatry, Neurology and Psychology at Yale University and Senior Research Scientist of Psychiatry at the Yale School of Medicine. He is also a Program Director of National Institutes of Health, Department of Defense and Department of Veterans Affairs Pain Management Collaboratory Coordinating Center.

<span class="mw-page-title-main">Prescription drug addiction</span> Medical condition

Prescription drug addiction is the chronic, repeated use of a prescription drug in ways other than prescribed for, including using someone else’s prescription. A prescription drug is a pharmaceutical drug that may not be dispensed without a legal medical prescription. Drugs in this category are supervised due to their potential for misuse and substance use disorder. The classes of medications most commonly abused are opioids, central nervous system (CNS) depressants and central nervous stimulants. In particular, prescription opioid is most commonly abused in the form of prescription analgesics.

Deni Carise is an American clinical psychologist, adjunct professor of psychiatry at the University of Pennsylvania and researcher in substance use disorder treatment.

References

  1. ↑ "Gold Family Scholarship". University of Florida Advancement. Retrieved 2022-01-19.
  2. ↑ "Gold named chair of UF psychiatry department". UF Health, University of Florida Health. 2009-02-20. Retrieved 2018-11-12.
  3. ↑ "60th Anniversary CME Event". UFHealth Department of Psychiatry. Retrieved 2018-11-12.
  4. 1 2 Gold, M. S.; Redmond Jr, D. E.; Kleber, H. D. (1978). "Clonidine blocks acute opiate-withdrawal symptoms". The Lancet. 2 (8090): 599–602. doi:10.1016/S0140-6736(78)92823-4. PMID   80526. S2CID   44253698.
  5. 1 2 Dackis, C. A.; Gold, M. S. (1985). "New concepts in cocaine addiction: The dopamine depletion hypothesis". Neuroscience and Biobehavioral Reviews. 9 (3): 469–77. doi:10.1016/0149-7634(85)90022-3. PMID   2999657. S2CID   45936344.
  6. ↑ Pagan, Marion B. "Down Our Street; Drug discovery", The Record , June 23, 1978. Accessed January 1, 2022, via Newspapers.com. "Dr. Mark S. Gold, a psychopharmacologist at the Connecticut Mental Health Center run by Yale University School of Medicine's psychiatry department, has found that Clonidine, a recent drug being prescribed for high blood pressure, prevents withdrawal symptoms in drug addicts. Dr. Gold, a 1967 graduate of Teaneck High School, warned that there are dangerous side effects which make it inadvisable for addicts to use Clonidine."
  7. ↑ "Dr. Mark Gold named UF's Distinguished Alumni Professor". Doctor Gator. Retrieved 2022-01-19.
  8. ↑ Rooney, Sonya. "Research Guides: WashU History FAQ: Distinguished Alumni Award Recipients". libguides.wustl.edu. Retrieved 2022-01-18.
  9. ↑ "History: UF College of Medicine Department of Neuroscience » History » Department of Neuroscience » College of Medicine » University of Florida" . Retrieved 2022-01-19.
  10. ↑ "Pioneering neuroscientist who founded UF's McKnight Brain Institute passes away". Doctor Gator. Retrieved 2022-01-25.
  11. ↑ "Washington University in St. Louis Proof of Graduation". Washington University in St. Louis.
  12. ↑ "University of Florida - Proof of Graduation". University of Florida.
  13. ↑ "Yale University - Proof of Graduation".
  14. ↑ Neurodiem. "Neurodiem". Neurodiem. Retrieved 2022-01-17.
  15. ↑ "Gold Family Scholarship". University of Florida Advancement. Retrieved 2022-01-19.
  16. ↑ "Discovery to Recovery newsletter message from the chairman – August 2012". UFHealth. Retrieved 2018-11-12.
  17. ↑ Bruijnzeel, Adrie W.; Marcinkiewcz, Catherine; Isaac, Shani; Booth, Matthew M.; Dennis, Donn M.; Gold, Mark S. (2007). "The effects of buprenorphine on fentanyl withdrawal in rats". Psychopharmacology. 191 (4): 931–941. doi:10.1007/s00213-006-0670-2. ISSN   0033-3158. PMID   17211652. S2CID   13388606.
  18. ↑ "Dr. Mark Gold named UF's Distinguished Alumni Professor". UFHealth. Retrieved 2018-11-12.
  19. ↑ "Dr. Mark Gold named UF's Distinguished Alumni Professor" (Press release). University of Florida. May 19, 2011. Archived from the original on August 12, 2011. Retrieved October 4, 2012.
  20. ↑ "Leading the Gators on the field and off". UF Health, University of Florida Health. 2011-11-18. Retrieved 2020-10-07.
  21. ↑ "Leading the Gators on the field and off". UF Health, University of Florida Health. 2011-11-18. Retrieved 2022-01-17.
  22. ↑ "A Symbol of Honor and Truth". UF University of Florida.
  23. ↑ "National Council". Institute for Public Health.
  24. ↑ Gold, M. S.; Kleber, H. D. (1979). "A rationale for opiate withdrawal symptomatology". Drug and Alcohol Dependence. 4 (5): 419–24. doi:10.1016/0376-8716(79)90074-7. PMID   228923.
  25. ↑ "Clonidine | Encyclopedia.com". www.encyclopedia.com. Retrieved 2020-06-23.
  26. ↑ Gold, MS; Washton, AM; Dackis, CA (1987). "The Physiology of Cocaine Craving and 'Crashing'". Archives of General Psychiatry. 44 (3): 298–300. doi:10.1001/archpsyc.1987.01800150122018. PMID   3827524.
  27. ↑ "Food for thought: UF researcher's book lays out evidence for food addiction". UF Health, University of Florida Health. 2012-10-03. Retrieved 2022-01-17.
  28. ↑ Gold, Mark S.; Byck, Robert (1978). "Endorphins, lithium and naloxone: their relationship to pathological and drug induced manic euphoric states". Natl Inst Drug Abuse Res Monogr Ser. 19: 192–209.
  29. ↑ Gold, Mark S. (1986-08-08). "Crack". JAMA: The Journal of the American Medical Association. 256 (6): 711. doi:10.1001/jama.1986.03380060037008. ISSN   0098-7484. PMID   3723767.
  30. ↑ Roehrich, H.; Gold, M. S. (1988). "800-COCAINE: origin, significance, and findings". The Yale Journal of Biology and Medicine. 61 (2): 149–155. ISSN   0044-0086. PMC   2590284 . PMID   3407211.
  31. ↑ Shuster, CR (2010). "The Highs and Lows of My Years at NIDA (1986-1992)". Drug and Alcohol Dependence. 107 (1): 92–95. doi:10.1016/j.drugalcdep.2009.05.003. PMID   20155880.
  32. ↑ "Food for thought: UF researcher's book lays out evidence for food addiction". UF Health, University of Florida Health. 2012-10-03. Retrieved 2020-10-07.
  33. ↑ Avena, N. M.; Potenza, M. N.; Gold, M. S. (2015). "Why are we consuming so much sugar despite knowing too much can harm us?". JAMA Internal Medicine. 175 (1): 145–6. doi:10.1001/jamainternmed.2014.6968. PMID   25560952.
  34. ↑ M. Avena, Nicole; E. Bocarsly, Miriam; G. Hoebel, Bartley; S. Gold, Mark (2011-09-01). "Overlaps in the Nosology of Substance Abuse and Overeating: The Translational Implications of "Food Addiction"". Current Drug Abuse Reviews. 4 (3): 133–139. doi:10.2174/1874473711104030133. PMID   21999687.
  35. ↑ "Yale Hosts Historic Conference on Food and Addiction". YaleNews. 2007-07-09. Retrieved 2021-04-20.
  36. ↑ Gold, Mark S. (1986). "Crack". JAMA: The Journal of the American Medical Association. 256 (6): 711. doi:10.1001/jama.1986.03380060037008. PMID   3723767.
  37. ↑ Bruijnzeel, A. W.; Qi, X.; Guzhva, L. V.; Wall, S.; Deng, J. V.; Gold, M. S.; Febo, M.; Setlow, B. (2016). "Behavioral Characterization of the Effects of Cannabis Smoke and Anandamide in Rats". PLOS ONE. 11 (4): e0153327. Bibcode:2016PLoSO..1153327B. doi: 10.1371/journal.pone.0153327 . PMC   4827836 . PMID   27065006.
  38. ↑ Thanos, Panayotis K.; Kim, Ronald; Delis, Foteini; Ananth, Mala; Chachati, George; Rocco, Mark J.; Masad, Ihssan; Muniz, Jose A.; Grant, Samuel C. (2017-02-08). "Correction: Chronic Methamphetamine Effects on Brain Structure and Function in Rats". PLOS ONE. 12 (2): e0172080. Bibcode:2017PLoSO..1272080T. doi: 10.1371/journal.pone.0172080 . ISSN   1932-6203. PMC   5298314 . PMID   28178354.
  39. ↑ Gold, Mark S.; Kobeissy, Firas H.; Wang, Kevin K.W.; Merlo, Lisa J.; Bruijnzeel, Adriaan W.; Krasnova, Irina N.; Cadet, Jean Lud (July 2009). "Methamphetamine- and Trauma-Induced Brain Injuries: Comparative Cellular and Molecular Neurobiological Substrates". Biological Psychiatry. 66 (2): 118–127. doi:10.1016/j.biopsych.2009.02.021. PMC   2810951 . PMID   19345341.
  40. ↑ Sekine, Y.; Ouchi, Y.; Sugihara, G.; Takei, N.; Yoshikawa, E.; Nakamura, K.; Iwata, Y.; Tsuchiya, K. J.; Suda, S. (2008-05-28). "Methamphetamine Causes Microglial Activation in the Brains of Human Abusers". Journal of Neuroscience. 28 (22): 5756–5761. doi: 10.1523/JNEUROSCI.1179-08.2008 . ISSN   0270-6474. PMC   2491906 . PMID   18509037.
  41. ↑ Blum, Kenneth; Cadet, Jean Lud; Gold, Mark S. (January 2021). "Psychostimulant use disorder emphasizing methamphetamine and the opioid -dopamine connection: Digging out of a hypodopaminergic ditch". Journal of the Neurological Sciences. 420: 117252. doi: 10.1016/j.jns.2020.117252 . ISSN   0022-510X. PMID   33279726.
  42. ↑ DuPont, Robert L.; McLellan, A. Thomas; White, William L.; Merlo, Lisa J.; Gold, Mark S. (2009). "Setting the standard for recovery: Physicians' Health Programs". Journal of Substance Abuse Treatment. 36 (2): 159–171. doi: 10.1016/j.jsat.2008.01.004 . ISSN   0740-5472. PMID   19161896.
  43. ↑ Merlo, Lisa J.; Gold, Mark S. (2008). "Prescription Opioid Abuse and Dependence Among Physicians: Hypotheses and Treatment". Harvard Review of Psychiatry. 16 (3): 181–194. doi:10.1080/10673220802160316. ISSN   1067-3229. PMID   18569039.
  44. ↑ Washton, Arnold M.; Gold, Mark S.; Pottash, A. Carter (1984). "Successful Use of Naltrexone in Addicted Physicians and Business Executives". Advances in Alcohol & Substance Abuse. 4 (2): 89–96. doi:10.1300/j251v04n02_08. ISSN   0270-3106. PMID   6524509.
  45. ↑ Shapira, Nathan A.; Lessig, Mary C.; Goldsmith, Toby D.; Szabo, Steven T.; Lazoritz, Martin; Gold, Mark S.; Stein, Dan J. (2003). "Problematic internet use: Proposed classification and diagnostic criteria". Depression and Anxiety. 17 (4): 207–216. doi: 10.1002/da.10094 . PMID   12820176. S2CID   13044242.
  46. ↑ Swenson, Sabrina; Blum, Kenneth; McLaughlin, Thomas; Gold, Mark S.; Thanos, Panayotis K. (2020-05-15). "The therapeutic potential of exercise for neuropsychiatric diseases: A review". Journal of the Neurological Sciences. 412: 116763. doi: 10.1016/j.jns.2020.116763 . ISSN   0022-510X. PMID   32305746.
  47. ↑ Wolf, David A. Patterson Silver; Gold, Mark (2020-04-15). "Treatment resistant opioid use disorder (TROUD): Definition, rationale, and recommendations". Journal of the Neurological Sciences. 411: 116718. doi:10.1016/j.jns.2020.116718. ISSN   0022-510X. PMID   32078842. S2CID   211029947.
  48. ↑ Gold, Mark S.; Baron, David; Bowirrat, Abdalla; Blum, Kenneth (2020-11-15). "Neurological correlates of brain reward circuitry linked to opioid use disorder (OUD): Do homo sapiens acquire or have a reward deficiency syndrome?". Journal of the Neurological Sciences. 418: 117137. doi: 10.1016/j.jns.2020.117137 . ISSN   0022-510X. PMC   7490287 . PMID   32957037.
  49. ↑ Wolf, David A. Patterson Silver; Gold, Mark (2020-04-15). "Treatment resistant opioid use disorder (TROUD): Definition, rationale, and recommendations". Journal of the Neurological Sciences. 411: 116718. doi:10.1016/j.jns.2020.116718. ISSN   0022-510X. PMID   32078842. S2CID   211029947.
  50. ↑ Thom, Browne; Mark, S. Gold; David, M. Martin (2021-02-28). "The Rapidly Changing Composition of the Global Street Drug Supply and Its Effects on High-Risk Groups for COVID-19". Current Psychopharmacology. 10 (2): 138–154. doi:10.2174/2211556010666210125124645. S2CID   234003033 . Retrieved 2021-05-18.
  51. ↑ "Adulterants in street drugs could increase susceptibility to COVID". www.mdedge.com. Retrieved 2021-05-18.
  52. ↑ "Journal of the Neurological Sciences | ScienceDirect.com by Elsevier". www.sciencedirect.com. Retrieved 2022-01-25.
  53. ↑ "Journal of the Neurological Sciences | Psychedelic & Interventional Psychiatry | ScienceDirect.com by Elsevier". www.sciencedirect.com. Retrieved 2022-01-25.
  54. ↑ Cottler, Linda B; Ajinkya, Shaun; Goldberger, Bruce A; Ghani, Mohammad Asrar; Martin, David M; Hu, Hui; Gold, Mark S (2014). "Prevalence of drug and alcohol use in urban Afghanistan: Epidemiological data from the Afghanistan National Urban Drug Use Study (ANUDUS)". The Lancet Global Health. 2 (10): e592–600. doi: 10.1016/S2214-109X(14)70290-6 . PMID   25304635.
  55. ↑ "US Patent Application for MEDICATION ADHERENCE MONITORING SYSTEM Patent Application (Application #20180017569 issued January 18, 2018) - Justia Patents Search". patents.justia.com. Retrieved 2022-01-17.
  56. ↑ Gardner, Christopher. "D.A.R.E. America to honor Yale Psychiatry alumnus". medicine.yale.edu. Retrieved 2021-10-05.
  57. ↑ "Addiction Medicine: Closing the Gap between Science and Practice" (PDF). The National Center on Addiction and Substance Abuse at Columbia University. 2012.
  58. ↑ Betty Ford Institute Consensus Panel (2007-10-01). "What is recovery? A working definition from the Betty Ford Institute". Journal of Substance Abuse Treatment. 33 (3): 221–228. doi:10.1016/j.jsat.2007.06.001. ISSN   0740-5472. PMID   17889294. S2CID   28965783.
  59. ↑ "Mark S. Gold, M.D. | World Affairs Council Jacksonville". www.worldaffairscounciljax.org. Retrieved 2020-06-23.
  60. ↑ "2019 Awards Dinner". APF. 2019-06-25. Retrieved 2020-06-23.
  61. ↑ "Mark Gold, MD, FASAM, Wins John P. McGovern Award". www.asam.org. Retrieved 2018-11-12.
  62. ↑ "The McKnight Brain Institute congratulates Mark S. Gold, M.D. on receiving the award for Distinguished International Scientist » McKnight Brain Institute » University of Florida". UFHealth. Retrieved 2019-07-29.
  63. ↑ "Gold named chair of UF psychiatry department". UF Health, University of Florida Health. 2009-02-20. Retrieved 2020-06-23.
  64. ↑ "Class of 2023 celebrates annual white coat ceremony". Doctor Gator. Retrieved 2020-06-23.
  65. ↑ "Dr. Mark Gold named UF's Distinguished Alumni Professor". Doctor Gator. Retrieved 2020-06-23.
  66. ↑ "Dr. Mark Gold named UF's Distinguished Alumni Professor". Doctor Gator. Retrieved 2021-04-20.
  67. ↑ "US Patent Application for MEDICATION ADHERENCE MONITORING SYSTEM Patent Application (Application #20180017569 issued January 18, 2018) - Justia Patents Search". patents.justia.com. Retrieved 2022-01-18.
  68. ↑ "US Patent for Compositions for controlling food intake and uses therefor Patent (Patent # 9,610,285 issued April 4, 2017) - Justia Patents Search". patents.justia.com. Retrieved 2022-01-18.
  69. ↑ "Mark Gold, M.D. | Axogen". www.axogeninc.com. Retrieved 2021-04-20.
  70. ↑ "Opioids, Heroin, New Look, Not Old Drugs". Drug Enforcement Administration Museum & Visitors Center. 2018-08-23.
  71. ↑ "New Look Old Drugs - 2018 Update". Drug Enforcement Administration Museum & Visitors Center. 2018-03-12.
  72. ↑ Oesterle, T. S.; Thusius, N. J.; Rummans, T. A.; Gold, M. S. (2019). "Medication-Assisted Treatment for Opioid-Use Disorder". Mayo Clinic Proceedings. 94 (10): 2072–2086. doi: 10.1016/j.mayocp.2019.03.029 . PMID   31543255.
  73. ↑ Srivastava, A. Benjamin; Gold, Mark S. (2018). "Beyond Supply: How We Must Tackle the Opioid Epidemic". Mayo Clinic Proceedings. 93 (3): 269–272. doi: 10.1016/j.mayocp.2018.01.018 . PMID   29502558.
  74. ↑ "Yale Psychiatry Grand Rounds: October 24, 2014". Yale School of Medicine.
  75. ↑ "What Can We Learn From Evaluating and Treating Physician Addicts?". Tulane University.
  76. ↑ "Cocaine and Addiction Researcher". National Drug Abuse & Heroin Summit.
  77. ↑ "Stimulant Summit". Cocaine, Meth & Stimulant Summit. November 2019.
  78. ↑ "FADAPConferencePresentations2019". www.fadap.org. Retrieved 2020-06-23.
  79. ↑ "Special Issue on "Addiction Medicine"". wfneurology.org. Retrieved 2020-10-07.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.